Heat Biologics, Inc. Logo

Heat Biologics, Inc.

HTBX

(1.2)
Stock Price

2,38 USD

-29.27% ROA

-31.02% ROE

-1.69x PER

Market Cap.

61.074.370,00 USD

1.49% DER

0% Yield

-1675.54% NPM

Heat Biologics, Inc. Stock Analysis

Heat Biologics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Heat Biologics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.53x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a minimal amount of debt (1%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

Negative ROE (-31.02%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-29.27%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Heat Biologics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Heat Biologics, Inc. Technical Stock Analysis
# Analysis Recommendation

Heat Biologics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Heat Biologics, Inc. Revenue
Year Revenue Growth
2011 187.787
2012 3.110 -5938.17%
2013 0 0%
2014 0 0%
2015 0 0%
2016 341.643 100%
2017 1.519.943 77.52%
2018 5.793.849 73.77%
2019 3.049.104 -90.02%
2020 2.947.969 -3.43%
2021 2.112.806 -39.53%
2022 849.672 -148.66%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Heat Biologics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 1.246.587
2012 902.938 -38.06%
2013 2.737.688 67.02%
2014 2.861.231 4.32%
2015 2.595.000 -10.26%
2016 9.330.677 72.19%
2017 8.267.549 -12.86%
2018 16.233.014 49.07%
2019 13.013.604 -24.74%
2020 12.938.895 -0.58%
2021 18.821.278 31.25%
2022 15.733.388 -19.63%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Heat Biologics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 4.138.285 100%
2017 0 0%
2018 7.025.212 100%
2019 9.431.015 25.51%
2020 15.001.203 37.13%
2021 16.828.229 10.86%
2022 15.106.492 -11.4%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Heat Biologics, Inc. EBITDA
Year EBITDA Growth
2011 -2.041.087
2012 -2.316.527 11.89%
2013 -8.625.881 73.14%
2014 -11.648.568 25.95%
2015 -19.815.000 41.21%
2016 -11.892.472 -66.62%
2017 -12.517.127 4.99%
2018 -16.482.024 24.06%
2019 -19.739.884 16.5%
2020 -25.716.585 23.24%
2021 -35.546.781 27.65%
2022 -31.171.116 -14.04%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Heat Biologics, Inc. Gross Profit
Year Gross Profit Growth
2011 187.787
2012 3.110 -5938.17%
2013 0 0%
2014 0 0%
2015 0 0%
2016 341.643 100%
2017 1.519.943 77.52%
2018 5.793.849 73.77%
2019 3.049.104 -90.02%
2020 2.947.969 -3.43%
2021 2.112.806 -39.53%
2022 849.672 -148.66%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Heat Biologics, Inc. Net Profit
Year Net Profit Growth
2011 -2.104.884
2012 -2.420.200 13.03%
2013 -8.711.348 72.22%
2014 -11.788.817 26.1%
2015 -20.295.000 41.91%
2016 -12.573.952 -61.41%
2017 -11.841.671 -6.18%
2018 -15.733.854 24.74%
2019 -20.017.568 21.4%
2020 -26.049.737 23.16%
2021 -35.400.807 26.41%
2022 -33.242.000 -6.49%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Heat Biologics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -79
2012 -91 12.22%
2013 -161 43.75%
2014 -126 -26.98%
2015 -175 27.59%
2016 -49 -255.1%
2017 -22 -133.33%
2018 -6 -250%
2019 -4 -50%
2020 -2 -300%
2021 -1 0%
2022 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Heat Biologics, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -1.661.312
2012 -2.075.455 19.95%
2013 -6.438.187 67.76%
2014 -10.288.103 37.42%
2015 -17.563.000 41.42%
2016 -13.569.653 -29.43%
2017 -6.365.055 -113.19%
2018 -22.305.264 71.46%
2019 -13.102.838 -70.23%
2020 -22.359.331 41.4%
2021 0 0%
2022 -11.305.416 100%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Heat Biologics, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -1.649.099
2012 -2.073.675 20.47%
2013 -6.388.868 67.54%
2014 -9.829.427 35%
2015 -17.447.000 43.66%
2016 -13.523.717 -29.01%
2017 -6.303.672 -114.54%
2018 -21.711.691 70.97%
2019 -12.837.650 -69.13%
2020 -22.021.359 41.7%
2021 0 0%
2022 -10.214.668 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Heat Biologics, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 12.213
2012 1.780 -586.12%
2013 49.319 96.39%
2014 458.676 89.25%
2015 116.000 -295.41%
2016 45.936 -152.53%
2017 61.383 25.16%
2018 593.573 89.66%
2019 265.188 -123.83%
2020 337.972 21.54%
2021 0 0%
2022 1.090.748 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Heat Biologics, Inc. Equity
Year Equity Growth
2011 -308.784
2012 -1.438.848 78.54%
2013 21.991.922 106.54%
2014 11.760.358 -87%
2015 4.051.000 -190.31%
2016 8.796.581 53.95%
2017 7.370.751 -19.34%
2018 30.289.550 75.67%
2019 13.571.602 -123.18%
2020 116.239.327 88.32%
2021 112.033.571 -3.75%
2022 105.842.442 -5.85%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Heat Biologics, Inc. Assets
Year Assets Growth
2011 182.067
2012 147.582 -23.37%
2013 23.020.066 99.36%
2014 15.916.170 -44.63%
2015 13.218.000 -20.41%
2016 8.896.599 -48.57%
2017 20.189.476 55.93%
2018 37.763.837 46.54%
2019 25.956.581 -45.49%
2020 124.194.642 79.1%
2021 120.961.233 -2.67%
2022 114.266.522 -5.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Heat Biologics, Inc. Liabilities
Year Liabilities Growth
2011 516.165
2012 1.662.691 68.96%
2013 1.302.921 -27.61%
2014 4.884.983 73.33%
2015 10.723.000 54.44%
2016 2.056.665 -421.38%
2017 14.408.567 85.73%
2018 7.520.891 -91.58%
2019 12.798.731 41.24%
2020 8.700.719 -47.1%
2021 8.927.662 2.54%
2022 9.568.034 6.69%

Heat Biologics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.08
Net Income per Share
-1.41
Price to Earning Ratio
-1.69x
Price To Sales Ratio
28.91x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0.53
EV to Sales
25.89
EV Over EBITDA
-1.54
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
-0.59
FreeCashFlow Yield
0
Market Cap
0,06 Bil.
Enterprise Value
0,05 Bil.
Graham Number
11.88
Graham NetNet
-0.03

Income Statement Metrics

Net Income per Share
-1.41
Income Quality
0
ROE
-0.31
Return On Assets
-0.29
Return On Capital Employed
-0.3
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-16.76
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
7.96
Research & Developement to Revenue
8.91
Stock Based Compensation to Revenue
0
Gross Profit Margin
1
Operating Profit Margin
-16.76
Pretax Profit Margin
-16.82
Net Profit Margin
-16.76

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.31
Return on Tangible Assets
-0.29
Days Sales Outstanding
11.41
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
31.99
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,32
Book Value per Share
4,46
Tangible Book Value per Share
4.46
Shareholders Equity per Share
4.46
Interest Debt per Share
0.07
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.18
Current Ratio
21.04
Tangible Asset Value
0,11 Bil.
Net Current Asset Value
0,09 Bil.
Invested Capital
0.01
Working Capital
0,09 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Heat Biologics, Inc. Dividends
Year Dividends Growth

Heat Biologics, Inc. Profile

About Heat Biologics, Inc.

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

CEO
Mr. Jeffrey Wolf
Employee
49
Address
627 DAVIS DRIVE, SUITE 400
Morrisville, 27560

Heat Biologics, Inc. Executives & BODs

Heat Biologics, Inc. Executives & BODs
# Name Age

Heat Biologics, Inc. Competitors